Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment

INTRODUCTION: BRCA1 mutation carriers have a significant lifetime risk of breast cancer, with their primary risk-reduction option being bilateral mastectomy. Preclinical work from our laboratory demonstrated that in BRCA1-deficient breast cells, oestrogen and its metabolites are capable of driving D...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Aideen M, Morris, Melanie, Gallagher, Rebecca, Boyd, Ruth, Carson, Hazel, Harkin, D Paul, Wielogorska, Ewa, Elliott, Christopher, Savage, Kienan I, McIntosh, Stuart A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Genetics and Genomics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318512/
https://www.ncbi.nlm.nih.gov/pubmed/30580266
http://dx.doi.org/10.1136/bmjopen-2018-023115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318512/
https://www.ncbi.nlm.nih.gov/pubmed/30580266
http://dx.doi.org/10.1136/bmjopen-2018-023115

Ejemplares similares